CureVac N.V.

3.42
-0.08 (-2.40%)
At close: Feb 14, 2025, 5:29 PM
undefined%
Bid n/a
Market Cap 766.68M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 0.47
PE Ratio (ttm) 7.27
Forward PE n/a
Analyst n/a
Ask n/a
Volume 68,350
Avg. Volume (20D) 140,880
Open 3.63
Previous Close 3.50
Day's Range 3.40 - 3.63
52-Week Range 2.11 - 4.81
Beta undefined

About 5CV.DE

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 cli...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 25, 2020
Employees 999
Stock Exchange XETRA
Ticker Symbol 5CV.DE
No News article available yet